JAZZ Stock Analysis: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$254.28
5.58 (2.24%)
▲
5d:
+3.8%
30d:
-0.23%
90d:
+6.22%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JAZZ trades at premium valuation expecting 5.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: JAZZ trades at premium valuation expecting 5.8% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$253.40
Based on 3.5% avg growth
INTRINSIC VALUE TODAY
$157.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $254.28, which is considered fair relative to its 30-day fair value range of $245.47 to $257.44. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.9) compared to its historical average (8.3). At these levels, the market is pricing in 5.8% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is approaching resistance at $261.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $281.35 (+10.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is approaching resistance at $261.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (6th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $281.35 (+10.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$245.47 -
$257.44
Company Quality Score
55/100
(HOLD)
Options IV Signal
6th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
71.9%
Protect Your Profits
Holding JAZZ? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 6th percentile)
- NEUTRAL: Mixed technical signals (52/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($281.35)
- BEARISH: Market expects 5.8% growth - appears too optimistic based on history
- NEUTRAL: Bottoming setup forming (52/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$245.47 -
$257.44
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$14.00
(5.5%)
Support & Resistance Levels
Support Level
$240.63
Resistance Level
$261.28
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.87
Wall Street Target
$281.35
(+10.6%)
Revenue Growth (YoY)
15.5%
Earnings Growth (YoY)
3.2%
Profit Margin
20.4%
Valuation Premium vs History
+5.8% premium
PE vs Historical
9.9 vs 8.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.8%
(market-implied from PE analysis)
1-Year Target
$269.03
(+6%)
2-Year Target
$284.63
(+12%)
3-Year Target
$301.14
(+18%)
3-Yr Target (if PE normalizes)
(PE: 10→8)
PE COMPRESSION
$253.29
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 2.9%)
$563.02
(+121%)
Base:
(SPY PE: 9.9, Growth: 2.9%)
$276.82
(+9%)
Bear:
(PE: 8.3, Growth: 2.9%)
$232.84
(-8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 17.27 | Current EPS (TTM): $14.40
Bull Case
$489.55
(+93%)
Analyst growth 78.9%, PE expands to 19.0
Base Case
$445.04
(+75%)
Market implied 78.9%, PE stable at 17.3
Bear Case
$169.12
(-34%)
Severe decline -20.0%, PE contracts to 14.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 4:26 PM ET
Data refreshes hourly during market hours. Next update: 5:26 PM
Data refreshes hourly during market hours. Next update: 5:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce C Cozadd
SELL
6000 shares
2026-04-01
Patricia Carr
SELL
1287 shares
2026-03-09
Norbert G Riedel
SELL
3415 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
